Literature DB >> 28718443

Developing Cures: Targeting Ontogenesis in Cancer.

Victor T G Lin1, Hawley C Pruitt2, Rajeev S Samant3, Lalita A Shevde4.   

Abstract

Cancer has long been known to histologically resemble developing embryonic tissue. Since this early observation, a mounting body of evidence suggests that cancer mimics or co-opts developmental processes to facilitate tumor initiation and progression. Programs important in both normal ontogenesis and cancer progression broadly fall into three domains: the lineage commitment of pluripotent stem cells, the appropriation of primordial mechanisms of cell motility and invasion, and the influence of multiple aspects of the microenvironment on the parenchyma. In this review we discuss how derangements in these developmental pathways drive cancer progression with a particular focus on how they have emerged as targets of novel treatment strategies.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28718443      PMCID: PMC5518628          DOI: 10.1016/j.trecan.2016.12.007

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  87 in total

1.  A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.

Authors:  Ralph Salloum; Trent R Hummel; Shiva Senthil Kumar; Kathleen Dorris; Shaoyu Li; Tong Lin; Vinay M Daryani; Clinton F Stewart; Lili Miles; Tina Young Poussaint; Charles Stevenson; Stewart Goldman; Girish Dhall; Roger Packer; Paul Fisher; Ian F Pollack; Maryam Fouladi; James Boyett; Rachid Drissi
Journal:  J Neurooncol       Date:  2016-06-27       Impact factor: 4.130

Review 2.  Regulation of costimulatory signal in maternal-fetal immune tolerance.

Authors:  Li-Ping Jin; Deng-Xuan Fan; Da-Jin Li
Journal:  Am J Reprod Immunol       Date:  2011-01-31       Impact factor: 3.886

3.  Collective invasion in breast cancer requires a conserved basal epithelial program.

Authors:  Kevin J Cheung; Edward Gabrielson; Zena Werb; Andrew J Ewald
Journal:  Cell       Date:  2013-12-12       Impact factor: 41.582

4.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

5.  The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility.

Authors:  Annette Säfholm; Johanna Tuomela; Jeanette Rosenkvist; Janna Dejmek; Pirkko Härkönen; Tommy Andersson
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

6.  Luminal cells are favored as the cell of origin for prostate cancer.

Authors:  Zhu A Wang; Roxanne Toivanen; Sarah K Bergren; Pierre Chambon; Michael M Shen
Journal:  Cell Rep       Date:  2014-08-28       Impact factor: 9.423

Review 7.  The front and rear of collective cell migration.

Authors:  Roberto Mayor; Sandrine Etienne-Manneville
Journal:  Nat Rev Mol Cell Biol       Date:  2016-01-04       Impact factor: 94.444

8.  A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma.

Authors:  Al B Benson; Zev A Wainberg; J Randolph Hecht; Dmitry Vyushkov; Hua Dong; Johanna Bendell; Fred Kudrik
Journal:  Oncologist       Date:  2017-02-28

9.  Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.

Authors:  Hong Jiang; Samarth Hegde; Brett L Knolhoff; Yu Zhu; John M Herndon; Melissa A Meyer; Timothy M Nywening; William G Hawkins; Irina M Shapiro; David T Weaver; Jonathan A Pachter; Andrea Wang-Gillam; David G DeNardo
Journal:  Nat Med       Date:  2016-07-04       Impact factor: 53.440

10.  Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.

Authors:  Kari R Fischer; Anna Durrans; Sharrell Lee; Jianting Sheng; Fuhai Li; Stephen T C Wong; Hyejin Choi; Tina El Rayes; Seongho Ryu; Juliane Troeger; Robert F Schwabe; Linda T Vahdat; Nasser K Altorki; Vivek Mittal; Dingcheng Gao
Journal:  Nature       Date:  2015-11-11       Impact factor: 49.962

View more
  7 in total

1.  Serotonin limits generation of chromaffin cells during adrenal organ development.

Authors:  Polina Kameneva; Victoria I Melnikova; Maria Eleni Kastriti; Anastasia Kurtova; Emil Kryukov; Aliia Murtazina; Louis Faure; Irina Poverennaya; Artem V Artemov; Tatiana S Kalinina; Nikita V Kudryashov; Michael Bader; Jan Skoda; Petr Chlapek; Lucie Curylova; Lukas Sourada; Jakub Neradil; Marketa Tesarova; Massimo Pasqualetti; Patricia Gaspar; Vasily D Yakushov; Boris I Sheftel; Tomas Zikmund; Jozef Kaiser; Kaj Fried; Natalia Alenina; Elena E Voronezhskaya; Igor Adameyko
Journal:  Nat Commun       Date:  2022-05-25       Impact factor: 17.694

2.  Conditional knockout of N-Myc and STAT interactor disrupts normal mammary development and enhances metastatic ability of mammary tumors.

Authors:  Hawley C Pruitt; Brandon J Metge; Shannon E Weeks; Dongquan Chen; Shi Wei; Robert A Kesterson; Lalita A Shevde; Rajeev S Samant
Journal:  Oncogene       Date:  2018-01-12       Impact factor: 9.867

Review 3.  Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Authors:  Davide Bedognetti; Michele Ceccarelli; Lorenzo Galluzzi; Rongze Lu; Karolina Palucka; Josue Samayoa; Stefani Spranger; Sarah Warren; Kwok-Kin Wong; Elad Ziv; Diego Chowell; Lisa M Coussens; Daniel D De Carvalho; David G DeNardo; Jérôme Galon; Howard L Kaufman; Tomas Kirchhoff; Michael T Lotze; Jason J Luke; Andy J Minn; Katerina Politi; Leonard D Shultz; Richard Simon; Vésteinn Thórsson; Joanne B Weidhaas; Maria Libera Ascierto; Paolo Antonio Ascierto; James M Barnes; Valentin Barsan; Praveen K Bommareddy; Adrian Bot; Sarah E Church; Gennaro Ciliberto; Andrea De Maria; Dobrin Draganov; Winson S Ho; Heather M McGee; Anne Monette; Joseph F Murphy; Paola Nisticò; Wungki Park; Maulik Patel; Michael Quigley; Laszlo Radvanyi; Harry Raftopoulos; Nils-Petter Rudqvist; Alexandra Snyder; Randy F Sweis; Sara Valpione; Roberta Zappasodi; Lisa H Butterfield; Mary L Disis; Bernard A Fox; Alessandra Cesano; Francesco M Marincola
Journal:  J Immunother Cancer       Date:  2019-05-22       Impact factor: 13.751

Review 4.  Re-Recognizing the Cellular Origin of the Primary Epithelial Tumors of the Liver.

Authors:  Jiliang Feng; Ruidong Zhu; Yu Yin; Shanshan Wang; Lei Zhou; Fudong Lv; Dawei Zhao
Journal:  J Hepatocell Carcinoma       Date:  2021-12-07

5.  Epigenetic Inheritance From Normal Origin Cells Can Determine the Aggressive Biology of Tumor-Initiating Cells and Tumor Heterogeneity.

Authors:  Jiliang Feng; Dawei Zhao; Fudong Lv; Zhongyu Yuan
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

6.  Disruption of STAT5A and NMI signaling axis leads to ISG20-driven metastatic mammary tumors.

Authors:  Heba Allah M Alsheikh; Brandon J Metge; Hawley C Pruitt; Sarah C Kammerud; Dongquan Chen; Shi Wei; Lalita A Shevde; Rajeev S Samant
Journal:  Oncogenesis       Date:  2021-06-02       Impact factor: 7.485

7.  Long intergenic non-coding RNA, regulator of reprogramming (LINC-ROR) over-expression predicts poor prognosis in renal cell carcinoma.

Authors:  Manal S Fawzy; Eman A Toraih; Aya El-Wazir; Marwa M Hosny; Dahlia I Badran; Amr El Kelish
Journal:  Arch Med Sci       Date:  2019-05-17       Impact factor: 3.318

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.